( ch was discovered through the same Anti...)Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR,Health

Azixa is part of EpiCept's MX90745 series of apoptosis inducers, which was licensed to Myriad as part of an exclusive, worldwide development and commercialization agreement. Under the terms of the agreement, Myriad is responsible for all clinical development and commercialization of compounds from this series. Myriad is currently conducting two Phase II clinical trials for Azixa, one in patients with primary brain cancer and the other in melanoma that has spread to the brain.

About EpiCept's ASAP Technology

Cancerous cells often exhibit unchecked growth caused by the disabling or absence of the natural process of programmed cell death, which is called apoptosis. Apoptosis is normally triggered to destroy a cell from within when it outlives its purpose or it is seriously damaged. One of the most promising approaches in the fight against cancer is to selectively induce apoptosis in

cancer cells, thereby checking, and perhaps reversing, the improper cell growth.

EpiCept's proprietary apoptosis screening technology can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells through the use of chemical genetics and its proprietary live cell high-throughput caspase-3 screening technology. Chemical genetics is a research approach investigating the effect of small molecule drug candidates on the cellular activity of a protein, enabling researchers to determine the protein's function. Using this approach with its proprietary caspase-3 screening technology, EpiCept researchers can focus their investigation on the cellular activity of small molecule drug candidates and their relationship to apoptosis.

This combination of chemical genetics and caspase-3 screening technology allows EpiC
'"/>